<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02183688</url>
  </required_header>
  <id_info>
    <org_study_id>155.8</org_study_id>
    <nct_id>NCT02183688</nct_id>
  </id_info>
  <brief_title>Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled Clinical Trial to Confirm the Rationale of the ASA + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To confirm the combination rationale for the combination of ASA + paracetamol + caffeine
      compared with the combination of ASA + paracetamol and the individual substances ASA,
      paracetamol, caffeine, and placebo administered orally to headache patients for two headache
      episodes
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 1998</start_date>
  <primary_completion_date type="Actual">January 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Calculated time to 50% pain relief, based on the pain intensity evaluated on a visual analogue scale (VAS)</measure>
    <time_frame>30 min., 1, 2, 3 and 4 hours after administration of the study medication</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with 50 % pain relief, evaluated on a VAS</measure>
    <time_frame>At least 2 hours after administration of the study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with 50 % pain relief, evaluated on a VAS</measure>
    <time_frame>At least 30 min., 1, 3, and 4 hours after administration of the study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity, evaluated on a VAS</measure>
    <time_frame>30 min., 1, 2, 3 and 4 hours after administration of the study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of weighted sum of pain intensity difference scores to maximum achievable sum of pain intensity differences (%SPIDweighted), evaluated on a VAS</measure>
    <time_frame>Up to the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of impairment of daily activities, evaluated on a 4-grade verbal scale (VRS)</measure>
    <time_frame>Before, 30 min., 1, 2, 3 and 4 hours after administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of headache</measure>
    <time_frame>Up to 48 hours after onset of each headache episode</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of efficacy by the patient, evaluated on a 4-grade VRS</measure>
    <time_frame>Within 12 hours after study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of tolerability by the patient, evaluated on a 4-grade VRS</measure>
    <time_frame>Within 12 hours after study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of tolerability by the investigator, evaluated on a 4-grade VRS</measure>
    <time_frame>After each administration of study drug during the treatment phase</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">1889</enrollment>
  <condition>Migraine Disorders</condition>
  <arm_group>
    <arm_group_label>ASA + paracetamol + caffeine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ASA + paracetamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ASA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Paracetamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Caffeine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose ASA</intervention_name>
    <arm_group_label>ASA + paracetamol + caffeine</arm_group_label>
    <arm_group_label>ASA + paracetamol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose ASA</intervention_name>
    <arm_group_label>ASA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose paracetamol</intervention_name>
    <arm_group_label>ASA + paracetamol + caffeine</arm_group_label>
    <arm_group_label>ASA + paracetamol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose paracetamol</intervention_name>
    <arm_group_label>Paracetamol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine</intervention_name>
    <arm_group_label>ASA + paracetamol + caffeine</arm_group_label>
    <arm_group_label>Caffeine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female or male out-patients aged between 18 and 65 years

          2. Diagnosis: Headache

               1. Tension type headache according to international headache society (IHS) Headache
                  Classification 2.1 (2.1.1 and 2.1.2) and/or

               2. Migraine according to IHS Headache Classification 1.1, 1.2.1 or

               3. Either a) or b), but cannot be distinctly classified

          3. The patient normally treats his/her headache successfully with non-prescription
             analgesics

          4. He/She has been suffering from headache for 12 months at least

          5. The headache first occurred before the age of 50 years

          6. During the previous three months, the patient has suffered from headache twice a month
             at least

          7. Informed consent according to §§ 40, 41 of the german medicines act and Good Clinical
             Practice (GCP)

          8. The patient seems likely to comply

        Exclusion Criteria:

          1. The patient treats his/her headache with prescription-only analgesics or migraine
             remedies

          2. The patient requires higher single doses of non-prescription analgesics to treat
             his/her headache than indicated in the patient information leaflet (e.g. more than 2
             tablets of Thomapyrin tablets)

          3. The patient normally treats his/her headache with non-prescription analgesics in
             effervescent tablet form

          4. The patient normally takes his/her non-prescription analgesics immediately at the
             onset of the first signs of a headache episode

          5. Headache occurs on more than 10 days per month

          6. The typical, untreated headache normally lasts less than 4 hours without treatment

          7. Women with a close association between the occurrence of headache and menstruation
             (menstrual migraine)

          8. Concomitant treatment with prescription-only and/or non-prescription analgesics

          9. Previous or concomitant treatment with antidepressants or antipsychotic medicines
             (previous treatment = within the previous 4 weeks)

         10. Previous or concomitant treatment with anti-rheumatic or anti-inflammatory drugs that
             may influence the headache symptoms (previous treatment = within the previous 4 days)

         11. Treatment of concomitant illnesses with drugs containing ASA (above a daily dose of
             100 mg per day), paracetamol or caffeine (e.g. for feverish common cold, etc.)

         12. Migraine prophylaxis or administration of drugs, indicated for any other reasons that
             influence headache symptoms, e.g.

             Propanolol, Metoprolol, Flunarizine, Cyclandelate, Valproic acid, Serotonin
             antagonists (pizotifen, methysergide, lisuride), Ergotamine, Dihydroergotamine,
             Benzodiazepines, Magnesium, Monoamine oxidase inhibitors

         13. Concomitant treatments with anti-emetics

         14. Drug abuse connected with the headache (defined as the administration of analgesics or
             other drugs for the treatment of acute headache on more than 10 days per month)

         15. Alcohol or drug abuse as defined by diagnostic and statistical manual of mental
             disorders (DSM-IV)

         16. Pregnancy and lactation

         17. Gastrointestinal ulcers

         18. Pathologically increased bleeding tendency

         19. Glucose-6-phosphate dehydrogenase deficiency

         20. Hypersensitivity to paracetamol, caffeine, ASA, salicylates, and other
             anti-inflammatory/anti-rheumatic agents or other allergenic substances that are
             relevant to the clinical trial

         21. Bronchial asthma

         22. Concomitant treatment with anticoagulants (e.g. coumarin derivates, heparin)

         23. Clinically relevant chronic or recurrent gastrointestinal symptoms

         24. Clinically relevant liver disorders

         25. Clinically relevant pre-existing renal damage

         26. Gilbert's syndrome

         27. Not successfully treated hyperthyroidism

         28. Simultaneous participation in another clinical trial

         29. Participation in another clinical trial within 4 weeks of entering this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 7, 2014</last_update_submitted>
  <last_update_submitted_qc>July 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

